KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Opko Health (OPK) Research & Development (2016 - 2025)

Opko Health's Research & Development history spans 16 years, with the latest figure at $32.8 million for Q4 2025.

  • For Q4 2025, Research & Development changed N/A year-over-year to $32.8 million; the TTM value through Dec 2025 reached $124.0 million, changed N/A, while the annual FY2025 figure was $124.0 million, 17.89% up from the prior year.
  • Research & Development reached $32.8 million in Q4 2025 per OPK's latest filing, up from $30.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $32.8 million in Q4 2025 to a low of $17.3 million in Q2 2022.
  • Average Research & Development over 5 years is $23.1 million, with a median of $19.5 million recorded in 2022.
  • Peak YoY movement for Research & Development: soared 78.05% in 2023, then crashed 32.72% in 2024.
  • A 5-year view of Research & Development shows it stood at $21.0 million in 2021, then fell by 7.04% to $19.5 million in 2022, then decreased by 0.69% to $19.4 million in 2023, then surged by 48.34% to $28.8 million in 2024, then increased by 13.91% to $32.8 million in 2025.
  • Per Business Quant, the three most recent readings for OPK's Research & Development are $32.8 million (Q4 2025), $30.1 million (Q3 2025), and $30.3 million (Q2 2025).